medRxiv preprint doi: https://doi.org/10.1101/2021.08.12.21261951; this version posted August 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Neutralization of VOCs including Delta one year post COVID-19 or 1

vaccine 2

- 3
- Sebastian Havervall[#], MD¹, Ulrika Marking[#], MD¹, Max Gordon, MD, PhD¹, Henry Ng, 4
- 5 MMSc^{1,2}, Nina Greilert-Norin, RN¹, Sarah Lindbo, PhD³, Kim Blom, PhD⁴, Peter Nilsson,
- PhD³, Mia Phillipson, PhD², Jonas Klingström, PhD^{4,5}, Sara Mangsbo, PhD⁶, Mikael Åberg, 6
- 7 PhD⁷, Sophia Hober[#], PhD³ and Charlotte Thålin[#], MD, PhD¹
- 8
- 9 1. Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden 10
- 2. Department of Medical Cell Biology and Science for Life Laboratory, Uppsala University, 11 Uppsala, Sweden 12
- 13 3. Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, 14 Sweden
- 15 4. Public Health Agency of Sweden, Solna, Sweden
- 5. Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, 16 17 Stockholm, Sweden
- 6. Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala 18 University, Uppsala, Sweden 19
- 20 7. Department of Medical Sciences, Clinical Chemistry and Science for Life Laboratory,
- Uppsala University, Uppsala, Sweden 21
- 22
- 23 # These authors contributed equally

- 25 **Keywords:** SARS-CoV-2; COVID-19; neutralizing antibodies; variants of concern; delta;
- immunity; vaccine 26
- 27
- 28
- **Corresponding author:** 29
- 30 Charlotte Thålin, MD, PhD
- 31 Karolinska institutet, Danderyd hospital
- 32 18288 Stockholm, Sweden
- Phone: +46 812355000, 33
- 34 Mail: charlotte.thalin@sll.se
- 35
- 36 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 Abstract

Background: SARS-CoV-2 variants, such as Alpha, Beta, Gamma and Delta, are raising
 concern about the efficiency of neutralizing antibodies (NAb) induced by wild-type infection or
 vaccines based on the wild-type spike.

41

Methods: We determined IgG and NAb against SARS-CoV-2 variants one year following
mild wild-type infection (n=104) and two-dose regimens with BNT162b2 (BNT/BNT) (n=67),
ChAdOx1 (ChAd/ChAd) (n=82), or heterologous ChAdOx1 followed by BNT162b2
(ChAd/BNT) (n=116).

46

Findings: Wild type spike IgG and NAb remained detectable in 80% (83/104) of 47 48 unvaccinated participants one year post mild infection. The neutralizing capacity was similar 49 against wild type (reference), Alpha (0.95 (0.92-0.98) and Delta 1.03 (0.95-1.11) but significantly reduced against Beta (0.54 (0.48-0.60)) and Gamma 0.51 (0.44-0.61). Similarly, 50 BNT/BNT and ChAd/ChAd elicited sustained capacity against Alpha and Delta (1.01 (0.78-51 1.31) and 0.85 (0.64-1.14)) and (0.96 (0.84-1.09) and 0.82 (0.61-1.10) respectively), with 52 reduced capacity against Beta (0.67 (0.50-0.88) and 0.53 (0.40-0.71)) and Gamma (0.12 53 (0.06-0.27) and 0.54 (0.37-0.80)). A similar trend was found following ChAd/BNT (0.74 (0.66-54 0.83) and 0.70 (0.50-0.97) against Alpha and Delta and 0.29 (0.20-0.42) and 0.13 (0.08-0.20) 55 against Beta and Gamma). 56 57

Interpretation: Persistent neutralization of the wide-spread Alpha and Delta variants one year after wild-type infection may aid vaccine policy makers in low-resource settings when prioritizing vaccine supply. The reduced capacity of neutralizing Beta and Gamma strains, but not the Alpha and Delta strains following both infection and three different vaccine regimens argues for caution against Beta and Gamma-exclusive mutations in the efforts to optimize next generation SARS-CoV-2 vaccines.

- Funding: A full list of funding bodies that contributed to this study can be found in theAcknowledgements section
- 67
- 68

69 Introduction

- Increasing data support that neutralizing antibodies following SARS-CoV-2 infection provide 70 71 a durable protection against reinfection (1-7), and vaccines have been shown effective in 72 constraining hospitalization and deaths associated with SARS-CoV-2 infection (8-11). However, emerging SARS-CoV-2 variants are raising concerns. Viral variants of concern 73 (VOC) with increased transmissibility, such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) 74 75 and B.1.617.2 (Delta), entail spike protein mutations conferring a fitness advantage affecting its biology, infectivity, transmissibility, and antigenicity (Figure 1). Spike alterations may 76 77 enable immune escape, specially voiced when it comes to the B.1.351 (Beta) and P1 78 (Gamma) VOC. Both display three mutations in the RBD region and particularly related to the 79 E484K mutation, which has been shown to reduce antibody binding and neutralization (12). Assessing the efficiency of humoral immunity following wild-type infection and current 80 vaccines against these globally spreading VOCs is important, both for understanding SARS-81 82 CoV-2 virulence and for the optimization of next generation SARS-CoV-2 vaccines (13-21). Using a high-throughput spike-specific IgG and pseudoneutralization assay, we determined 83 the SARS-CoV-2 IgG antibody levels and neutralization capacity against the wild-type virus 84 and VOCs one year following SARS-CoV-2 wild-type infection or following three different 85
- vaccine regimens employing the BNT162b2 (Comirnaty, Pfizer-BioNTech) and ChAdOx1
- nCoV-19 (Vaxzevria, AstraZeneca) vaccines.
- 88

89 Methods

The COMMUNITY (COVID-19 Biomarker and Immunity) study (22, 23) investigates immune 90 91 responses after COVID-19 infection and vaccination. Between April 15 and May 8, 2020, 92 2149 healthcare workers (HCW) at Danderyd Hospital, Stockholm, Sweden were included. 93 All study participants are invited for repeated blood samplings every four months. Serology 94 was performed using two assays; a multiplex antigen bead assay (FlexMap3D, Luminex Corp) (24) measuring spike-specific IgG and the V-PLEX SARS-CoV-2 Panel 13 (Meso 95 96 Scale Diagnostics, USA) measuring spike-specific IgG and their neutralizing capacity (pseudo-neutralizing spike-ACE2 assay) against SARS-CoV-2 wild-type and variants B.1.1.7 97 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta). Clinical sensitivity, specificity, 98 and cut-off values for the wild-type strain for both MSD assays (K15463U (IgG), K15466U 99 (ACE2)) were established by ROC analysis of 200 commercially sourced pre-2109 healthy 100 adults and 214 PCR-confirmed COVID-19 patients by the manufacturer. Values for each 101 assay can be obtained from kit insert Appendix G found at the manufacturer's homepage 102 103 http://www.mesoscale.com.

This sub study included one group with all study participants that were confirmed SARS-105 CoV-2 Spike IgG positive by both assays at study inclusion, who attended all follow-ups and 106 107 who were not yet vaccinated by the 12-month follow-up. All participants reported mild 108 COVID-19 symptoms, and none were hospitalized. Blood samples were also obtained from 109 three groups of vaccinated individuals: all participants who received two doses of BNT162b2 vaccine (BNT x 2; median dose interval 21 days (IQR 21-21), two doses of ChAdOx1 nCoV-110 111 19 vaccine (ChAd x 2; median dose interval 81.5 days (IQR 77-84)) or a prime dose of ChAdOx1 nCoV-19 vaccine and booster dose with BNT162b2 vaccine (ChAd + BNT; median 112 dose interval 90 days (IQR 86-94)). Blood samples were collected 30-55 days following the 113 BNT x 2 regimens, and 14-22 days following regimens with ChAd priming. The study was 114 115 approved by the Swedish Ethical Review Authority (dnr 2020-01653), and written informed consent was obtained from all study participants. 116

117

118 Statistical analysis

We used mixed effect modelling with subject id as random effect where the outcome during modelling was converted using the log2-function. Interaction between strain and timespans was tested in two subsequent steps, baseline vs any other follow-up, and within the followups. The models were compared using ANOVA. Analyses were performed in R version 4.1.0 with nlme-package (v. 3.1.152). The estimates were compared using the contrast-package (v. 0.22). Each model was adjusted for age and sex. Correlation analysis was performed using Spearman.

126

127 Role of the funding source

128 The funders had no role in the design and conduct of the study; collection, management,

analysis, and interpretation of the data; preparation, review, or approval of the manuscript;

and decision to submit the manuscript for publication.

131

132 **Results**

A total of 104 study participants who were confirmed spike IgG positive at study inclusion 133 134 and attended all four-month follow-ups remained unvaccinated at the 12-month follow-up (median age 42 (IQR 31.75-51.25), 88% female). In line with prior reports (3, 4, 25) the levels 135 of both spike binding IgG and neutralizing antibodies (NAb) against the SARS-CoV-2 wild-136 type strain declined over the first few months, but thereafter remained stable, (Fig 2 A-B), 137 with similar trends for all SARS-CoV-2 VOCs (Table S1). High spike IgG and NAb levels at 138 baseline correlated with high levels 12 months post infection against the wild-type virus and 139 all four VOCs (all r > 0.5 and maximum p < 0.0001). Wild-type spike IgG remained detectable 140

in 91% (95/104), 84% (87/104) and 80% (83/104) of the participants at the 4-, 8- and 12-

month follow-up, respectively, with corresponding Wild-type NAb being 96% (100/104), 93%
(97/104) and 91% (95/104).

144

Differences in neutralizing capacity against the SARS-CoV-2 wild-type and VOCs using
samples taken 12 months post infection was determined by quantile regression adjusting for
age and sex. With the neutralizing capacity against the SARS-CoV-2 wild-type strain as the
reference, the capacity of the antibodies induced by the natural infection of the wild-type
virus was only slightly reduced against the B.1.1.7 (Alpha) and similar against the B.1.617.2
(Delta) strain. There was, however, a notable and reduction against the B.1.351 (Beta) and
P.1 (Gamma) strains (Figure 2C, 3 and Table S2).

152

153 We next investigated differences in neutralizing capacity against the SARS-CoV-2 wild-type and VOCs following vaccination with either two doses BNT162b2 vaccine (n=67, median age 154 52 (IQR 41-59), 84% female), two doses ChAdOx1 nCoV-19 vaccine (n=82, median age 51 155 (IQR 42-57), 88% female) or a prime dose of ChAdOx1 nCoV-19 vaccine and booster dose 156 with BNT162b2 vaccine (n=116, median age 50 (IQR 40-56), 92% female). Similar to the 157 responses observed 12 months post infection, the neutralizing capacity following the 158 BNT/BNT and ChAd/ChAd vaccine regimens were similar against the B.1.1.7 (Alpha), 159 B.1.617.2 (Delta) and wild-type strains. However, there was a reduction against the B.1.351 160 (Beta) and P.1 (Gamma) strains (Figure 2 D-E, 3 and Table S2). The ChAd/BNT vaccine 161 162 regimen elicited antibodies capable of similar neutralization against the B.1.617.2 (Delta) and the wild-type strain, but with slightly lower neutralizing capacity against the B.1.1.7 (Alpha) 163 164 strain. NAb titers against the B.1.351 (Beta) and P.1 (Gamma) strains were, as with the two 165 other vaccine regimens, significantly reduced (Figure 2F and 3 and Table S2).

166

167 Discussion

168 Our results demonstrate initial reductions but thereafter stable SARS-CoV-2 IgG levels over

- 169 12 months following mild SARS-CoV-2 infection. Circulating and readily detectable
- 170 antibodies are crucial in the assessment and diagnosis of prior infection both on an individual
- and population-based level. We furthermore show that these antibodies display neutralizing
- abilities against the B.1.1.7 (Alpha) and B.1.617.2 (Delta) strains similar to those against the
- 173 wild-type strain, and that this capacity is maintained over time, implying a robust immunity
- also against these now globally spreading strains. Notably, neutralizing capacity was,
- however, significantly reduced against the B.1.351 (Beta) and P.1 (Gamma) strains.

176 The two vaccines used in the studied regimens are both based on the wild-type SARS-CoV-2

177 spike protein. We found that these three vaccine regimens elicited a similar response as

infection with the wild-type strain. Although the virulence of a certain VOC as well as the level 178 of evoked immune protection is dependent on a multitude of features, it is highly influenced 179 by the interaction between the viral spike protein and the host ACE2 receptor. A VOC with 180 181 higher affinity to ACE2 potentially needs fewer virions to be infective. Further, escape 182 mutants able to evade the immune system might appear as the immunity develops globally. To date, there is published data showing a higher affinity to ACE2 for two (B.1.1.7 (Alpha) 183 184 and B.1.351 (Beta)) of the four VOCs (26), while data regarding the other two VOCs (P.1 (Gamma), and B.1.617.2 (Delta)) is still missing. Our data indicate no loss of neutralisation of 185 186 lineage B.1.1.7 (Alpha), suggesting that the higher transmissibility depends on viral 187 characteristics such as the reported higher affinity gained by the N501Y. The additional 188 mutations in positions 417 and 484 are affecting the neutralizing possibility where a threonine in position 417 (in P.1 (Gamma)) appears to give a negative effect for the BNT vaccine 189 (Figure 1 and 3). The higher transmissibility of lineage B.1.617.2 (Delta) does not seem to be 190 191 based on a lower antibody protection due to the two mutations in RBD alone. However, a higher rate of proliferation has been reported (27) for this VOC. The major concern regarding 192 this VOC does not seem to stem from immune escape but could instead be due to other 193 improved fitness characteristics. 194

So far, the E484 mutation has been reported to affect antibody binding and neutralization
(28) and as such, both B.1.351 (Beta) and P.1 (Gamma) would be at risk of escaping
immune control induced by the wild-type strain or current vaccines, which is corroborated by
our IgG and Nab results.

199

Limitations of this study include the observational and single-center design and the large portion of women. Strengths include the long follow-up and different vaccine regimes within the same study protocol along with the baseline sample opportunity against the wild-type and VOC strains.

204

Our findings of long-lasting neutralization of the widely spreading B.1.1.7 (Alpha) and
B.1.617.2 (Delta) variants one year after wild type infection may aid vaccine policy makers in
low-resource settings when prioritizing limited vaccine supply. Furthermore, the globally
reduced capacity of neutralizing B.1.351 (Beta) and P.1 (Gamma) strains, but not the B.1.1.7
(Alpha) and B.1.617.2 (Delta) strains following both infection and three different vaccine
regimens argues for caution against B.1.351 (Beta) and P.1 (Gamma)-exclusive spike
protein mutations in the efforts to optimize next generation SARS-CoV-2 vaccines.

214 Acknowledgements

- 215 This work was funded by Jonas & Christina af Jochnick foundation; Lundblad family
- foundation; Region Stockholm; Knut and Alice Wallenberg foundation; Science for Life
- 217 Laboratory (SciLifeLab); Erling-Persson family foundation; CIMED and the Swedish
- 218 Research Council.
- 219

220 Conflict of Interest

- 221 SoH has participated on Astra Zeneca COVID-19 SCG Virtual Advisory Board. Otherwise,
- the authors declare no competing interests.
- 223

224 Author contribution

- SeH, UM, and CT had full access to all the data in the study and takes responsibility for the
- integrity of the data and the accuracy of the data analysis.
- 227 SeH, UM, SoH, and CT designed the study, and drafted the manuscript. MG made the
- statistical analyses. NG, HN, MÅ conducted the analysis and the administrative and material
- support. SeH, UM, SL, KB, PN, SM, JK, MP, MÅ, SoH, PN, CT interpreted the data, and all
- authors critically revised the manuscript. SoH, PN, CT obtained funding. MP, MÅ, SoH, CT
- supervised. All authors had final responsibility for the decision to submit for publication.
- 232

233 Data sharing

- The anonymized datasets generated during and/or analyzed during the current study are
- available from the corresponding author on reasonable request.
- 236
- 237

238 References

239 Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, et al. 1. 240 Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery 241 Vessel Outbreak with a High Attack Rate. Journal of Clinical Microbiology. 2020;58(11):e02107-20. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. 242 2. 243 A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of 244 protection, and association with severity. Nature Communications. 2020;11(1):4704. 245 3. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust 246 neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020. 247 Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to 4. 248 SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529). 249 Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing 5.

antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12(1):63.

2516.Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally252enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature.

253 2021;595(7867):426-31.


All rights reserved. No reuse allowed without permission.

254 7. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2 255 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021. 256 8. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and 257 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 258 randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. 259 9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and 260 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 261 2020;383(27):2603-15. 262 10. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine 263 effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in 264 residents of long-term care facilities in England (VIVALDI): a prospective cohort study. The Lancet 265 Infectious Diseases. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA 266 11. 267 Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. 268 2021;384(15):1412-23. 269 12. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. 270 Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect 271 recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463-76.e6. 272 Neuzil KM. Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control. 13. 273 New England Journal of Medicine. 2021;384(20):1952-4. 274 Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in 14. 275 Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel). 2021;9(3). 276 Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased resistance of 15. 277 SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021;29(5):747-51.e4. 278 16. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. 279 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021. 280 17. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 281 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021. 282 Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-18. 283 CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1899-909. 284 19. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the 285 ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885-286 98. 287 20. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. 288 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of 289 Medicine. 2021. 290 21. Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, et al. SARS-CoV-2 291 Variants and Vaccines. New England Journal of Medicine. 2021;385(2):179-86. 292 22. Rudberg AS, Havervall S, Manberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-293 CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun. 294 2020;11(1):5064. 295 23. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms 296 and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. 297 JAMA. 2021. 298 24. Hober S, Hellström C, Olofsson J, Andersson E, Bergström S, Jernbom Falk A, et al. 299 Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex 300 serological COVID-19 assay. Clinical & Translational Immunology. 2021;10(7):e1312. 301 Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal 25. 302 observation and decline of neutralizing antibody responses in the three months following SARS-CoV-303 2 infection in humans. Nature Microbiology. 2020;5(12):1598-607.

304 305 306 307 308 309 310 311 312 313	 Ramanathan M, Ferguson ID, Miao W, Khavari PA. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. The Lancet Infectious Diseases. 2021;21(8):1070. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815-21. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology. 2021;19(7):409-24. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects.
314	Nature Structural & Molecular Biology. 2020;27(8):763-7.
315	
316	
317	
318	
319	
320	
321	
322	
323	
324	
325	
326	
327	
328	
329	
330	
331	
332	
333	
334	
335	
336	
337	
338	
339	
340	
341	
342	
343	

344 **Figures**

345



346 347

Figure 1. A top view of the structure of a furin-cleaved spike protein of SARS-CoV-2 is

shown (6ZGG) with the receptor binding domain (RBD) of the three chains colored in light

350 blue. Positions of RBD that are mutated in the four most common VOCs are colored in red.

RBD of the B chain is shown in the erected state (29). The different mutations included in the


352 four VOCs are listed in the figure.


353

354

355

356








Figure 3. Forest plot of regression output for strain type neutralization. Estimates are
multiplicative, i.e. 0.5 corresponds to a 50% reduction in antibody response in relation to the
wild-type strain. The model is a mixed effect quantile regression for the median. BNT;

- 376 BNT162b2 vaccine, ChAd; ChAdOx1 nCoV-19

Supplementary data

Table S1

	Base	eline	4m		8m		12m	
	Median	IQR	Median	IQR	Median	IQR	Median	IQR
IgG (kAU/ml)								
Wild type	12.6 (6.3-23.3)	6.0	(3.6-10.0)	5.5 (2.6-8.3)	4.0 ((2.1-7.6)
Alpha (B.1.1.7)	9.9 (5.4-17.5)	5.9	(3.3-9.9)	4.9 (2.6-8.1)	4.0 ((2.2-7.2)
Beta (B.1.351)	5.4 (3.2-11.2)	3.7	(2.2-6.4)	3.8 (1.9-6.5)	2.8 ((1.6-5.4)
Delta (B.1.617.2)) 4.9 (2.8-12.5)	3.5	(2.1-6.1)	3.5 (1.8-5.8)	2.6 ((1.5-5.1)
Gamma (P.1)	6.7 (3.1-14.0)	3.5	(2.1-6.4)	3.7 (1.7-6.3)	2.6 ((1.3-5.0)
Neutralizing ab (A	.U/ml)							
Wild type	3.6	(2.3-7.9)	1.7	(1.2-2.6)	1.3 (0.9-1.7)	1.1 ((0.8-1.5)
Alpha (B.1.1.7)	2.8	(2.0-6.1)	1.5	(1.1-2.5)	1.2 (0.9-1.8)	1.0 ((0.7-1.6)
Beta (B.1.351)	1.1	(0.8-2.2)	0.7	(0.5-1.1)	0.6 (0.4-0.9)	0.5 ((0.4-0.9)
Delta (B.1.617.2)	3.7	(2.1-7.6)	1.6	(0.9-2.3)	1.1 (0.6-1.7)	1.2 ((0.7-1.7)
Gamma (P.1)	1.2	(0.8-2.4)	0.8	(0.4-1.3)	0.5	(0.1-0.9)	0.6	(0.4-0.9)

Median and interquartile range for antibody response for SARS-CoV-2 variants (n=104)

Table S2 422

423

	Est.	CI
Natural infection		
One year		
Wild-type	1.00	(reference)
Alpha (B.1.1.7)	0.95	(0.92 - 0.98)
Beta (B.1.351)	0.54	(0.48 - 0.60)
Gamma (P.1)	0.51	(0.44 - 0.61)
Delta (B.1.617.2)	1.03	(0.95 - 1.11)
Vaccine regimen BNT/BNT		
Wild-type	1.00	(reference)
Alpha (B.1.1.7)	1.01	(0.78 - 1.31)
Beta (B.1.351)	0.67	(0.50 - 0.88)
Gamma (P.1)	0.12	(0.06 - 0.27)
Delta (B.1.617.2)	0.85	(0.64 - 1.14)
ChAd/BNT		
Wild-type	1.00	(reference)
Alpha (B.1.1.7)	0.74	(0.66 - 0.83)
Beta (B.1.351)	0.29	(0.20 - 0.42)
Gamma (P.1)	0.13	(0.08 - 0.20)
Delta (B.1.617.2)	0.70	(0.50 - 0.97)
ChAd/ChAd		
Wild-type	1.00	(reference)
Alpha (B.1.1.7)	0.96	(0.84 - 1.09)
Beta (B.1.351)	0.53	(0.40 - 0.71)
Gamma (P.1)	0.54	(0.37 - 0.80)
Delta (B.1.617.2)	0.82	(0.61 - 1.10)

Regression output for neutralization against different viral strains. Comparisons are conducted within the separate groups, with neutralization against wild-type within each group as reference. Estimates are multiplicative, i.e. 0.5 corresponds to a 50% reduction in antibody response. Each separate group is a quantile regression model for the median with mixed effect.